Sanofi-Aventis: Treating Diabetes
Term Project
Introduction: | Sanofi-Aventis U.S., based in Bridgewater, NJ, and employing 15,000 people across the country, is part of a leading global pharmaceutical company that discovers, develops, and produces markets innovative therapies that enhance people’s lives. Their extensive research and development efforts are focused on health care challenges in cardiology, oncology and internal medicine, as well as metabolic diseases, central nervous system disorders and vaccines. LANTUS is one of the major key products of Sanofi-Aventis that is used for treating Diabetes. | | |
LANTUS is a long- acting human insulin analog indicated to improve glycemic control in adults and children with type 1 diabetes mellitus and in adults …show more content…
The firm conducts research and produces pharmaceutical products medicines in fields of seven therapeutic areas: cardiovascular diseases, oncology, internal medicine, metabolic disorders (especially diabetes), central nervous system disorders and thrombosis. Sanofi- Aventis is a global pharmaceutical group focused on the research, development, manufacture and marketing of healthcare products. It offers Rx (prescription) drugs, OTC/OTX (over-the counter/combined OTC and Rx drugs), generics, vaccines and animal health products in about 100 counties across the world. The main strategy of the company to achieve their goals is based on their three priorities. They …show more content…
This demonstrates that a significant proportion of total revenues are accounted for by the base business, which comprises a large number of therapeutically-diverse products which can be grouped into 'bespoke portfolios' tailored for specific regions or individual countries.
In the likelihood that Sanofi-Aventis focuses future M&A activity on smaller scale acquisitions, it stands to reason that the company is less likely to enter into another mega-merger in the short to medium term, thereby avoiding a raft of large scale M&A activity that could continue over the next 18-24 months. Cost containment, as opposed to the symbiotic relationship between two diverse portfolios/R&D pipelines, is integral to mega-mergers.
If Sanofi-Aventis can avoid pressure to follow such an avenue its current strategy should shape a much more flexible and potentially innovative company in the long term. Despite a number of products in its late stage R&D pipeline, these expires will signal a weakening of Sanofi-Aventis's oncology portfolio, given that both brands are cornerstone
Introduction: | Sanofi-Aventis U.S., based in Bridgewater, NJ, and employing 15,000 people across the country, is part of a leading global pharmaceutical company that discovers, develops, and produces markets innovative therapies that enhance people’s lives. Their extensive research and development efforts are focused on health care challenges in cardiology, oncology and internal medicine, as well as metabolic diseases, central nervous system disorders and vaccines. LANTUS is one of the major key products of Sanofi-Aventis that is used for treating Diabetes. | | |
LANTUS is a long- acting human insulin analog indicated to improve glycemic control in adults and children with type 1 diabetes mellitus and in adults …show more content…
The firm conducts research and produces pharmaceutical products medicines in fields of seven therapeutic areas: cardiovascular diseases, oncology, internal medicine, metabolic disorders (especially diabetes), central nervous system disorders and thrombosis. Sanofi- Aventis is a global pharmaceutical group focused on the research, development, manufacture and marketing of healthcare products. It offers Rx (prescription) drugs, OTC/OTX (over-the counter/combined OTC and Rx drugs), generics, vaccines and animal health products in about 100 counties across the world. The main strategy of the company to achieve their goals is based on their three priorities. They …show more content…
This demonstrates that a significant proportion of total revenues are accounted for by the base business, which comprises a large number of therapeutically-diverse products which can be grouped into 'bespoke portfolios' tailored for specific regions or individual countries.
In the likelihood that Sanofi-Aventis focuses future M&A activity on smaller scale acquisitions, it stands to reason that the company is less likely to enter into another mega-merger in the short to medium term, thereby avoiding a raft of large scale M&A activity that could continue over the next 18-24 months. Cost containment, as opposed to the symbiotic relationship between two diverse portfolios/R&D pipelines, is integral to mega-mergers.
If Sanofi-Aventis can avoid pressure to follow such an avenue its current strategy should shape a much more flexible and potentially innovative company in the long term. Despite a number of products in its late stage R&D pipeline, these expires will signal a weakening of Sanofi-Aventis's oncology portfolio, given that both brands are cornerstone